NABI BIOPHARMACEUTICALS RECEIVES FAVORABLE OPINION FROM THE COMMITTEE ON ORPHAN MEDICINAL PRODUCTS

Nabi Biopharmaceuticals (Nasdaq: NABI) today announced that it received a favorable opinion in Europe regarding Orphan Medicinal Product (OMP) designation for Altastaph(TM) (human Staphylococcus aureus immunoglobulin) for the treatment of Staphylococcus aureus bacteremia. OMP designation acknowledges the significant medical need for a product and can provide development and commercialization advantages. Based upon this favorable opinion, Nabi Biopharmaceuticals expects to receive the formal OMP designation from the European Commission later this year.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-22-2005/0004113074&EDATE=)